420 with CNW — Cannabis MSOs Set Sights on Growing Wholesale Divisions

A top cannabis executive recently revealed that several cannabis multistate operators (MSOs) intend to prioritize their wholesale divisions in 2024. Jamie Mendola, the national head of wholesale/purchasing, western region regional manager and chief business development officer at Florida-based multistate operator Ayr Wellness, says that while MSOs focused on wholesale last year, the division will become an even greater priority this year.

Mendola notes that reduced capital will decrease the odds of company growth through mergers and acquisitions or by obtaining more licenses, forcing MSOs to turn their focus to wholesale. He adds that with many vertically integrated cannabis businesses in states such as New York, Massachusetts and Illinois reaching or nearly reaching their total number of retail licenses, wholesale will take higher priority.

The cannabis executive predicted that the “vast majority” of the MSOs in America’s state-level cannabis sector are focusing on organic growth. This growth will likely come from the wholesale division, Mendola said, especially in markets that still haven’t transitioned from medical marijuana to recreational cannabis. However, MSOs will have to overcome challenges such as low cannabis prices to grow their wholesale divisions.

Mendola notes that in Ayr’s case, a double-digit increase in wholesale sales volumes in 2023 was significantly undermined by a double-digit reduction in wholesale prices. Although the company saw notable growth through the end of the year, Mendola says price compression masked a lot of this growth. Limited vertical integration among the newest entrants into the cannabis retail market could help stabilize wholesale cannabis prices as these retailers will need wholesale partners to supply products regularly, Mendola says.

Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) in New York is also hoping the state’s increasing number of retail cannabis retailers leads to positive headwinds for the company’s wholesale division. The company’s CEO Matt Darin said in a recent interview that Curaleaf had already begun selling its cannabis products in the wholesale market, likely in anticipation of the flood of demand expected to come from the retail division.

Unfortunately, this strategy won’t be as effective in mature markets such as Massachusetts where both retail and wholesale divisions are at capacity. MSOs in Massachusetts built massive cultivation facilities when there was easier access to capital and cannabis prices and averaged $3,000 per pound.

Ben Burnstein, a senior associate in charge of corporate development at New York-based cannabis wholesale platform Leaflink, says wholesale prices have now dropped to around $1,400 per pound, partly due to reduced foot traffic in brick-and-mortar stores.

Wholesalers can ensure they remain competitive in the increasingly saturated market by building value for their retail partners through varied product offerings, reliability and consistency, Dazed cannabis cofounder Chris Vianello says.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Suggests Marijuana Isn’t Effective as Treatment for Opioid Addiction

A recent study involving 8,367 patients undergoing treatment for opioid-use disorder has challenged the notion that cannabis serves as an effective remedy for overcoming opioid addiction. The study, published in “The American Drug and Alcohol Abuse” Journal, revealed that marijuana, when used outside of medical supervision, fails to exert any noteworthy impact on opioid consumption.

The study carries significant implications for treatment programs in the United States, some of which impose a prerequisite for patients to abstain from marijuana before qualifying for life-saving interventions. This is predicated on the idea that people who use cannabis are more inclined to use opioids for nonmedical purposes.

The study also casts doubt on the competing and growingly popular theory that suggests cannabis can help wean individuals with opioid-use disorder off of opioids. Opioids, while effective in alleviating pain, harbor the risk of addiction, contributing to an ongoing crisis in the United States.

The nation witnesses approximately 120 daily deaths resulting from opioid-related overdoses, while the economic toll of opioid addiction and related fatalities surpasses $1 trillion annually.

While the most common justification for medical cannabis legalization is pain management, more and more states are expanding the list of acceptable cannabis-treatable diseases to include problems that can be treated with opioids, including the disorder in certain instances. The researchers attributed this in part to the perception that cannabis is less dangerous now that it is allowed for recreational use in several states.

Nevertheless, the study fails to provide clarity on whether marijuana aids or impedes the treatment of opioid addiction. While certain studies suggest that marijuana helps mitigate pain and alleviate opioid-withdrawal symptoms, others propose that it may elevate the likelihood of reverting to opioid use.

The study, a meta-analysis consolidating data from 10 long-term trials, spanned an average of 10 months. Participants were monitored for nonmedical opioid use, encompassing the consumption of opioids not prescribed to them and exceeding prescribed dosages. The study compared the frequency of such use between cannabis users and nonusers.

The results revealed no discernible connection between marijuana use and the rates of nonprescribed opioid use. According to the authors, the results neither support nor refute worries that cannabis use may increase the use of nonprescribed opioids in patients receiving treatment for opioid addiction.

The authors cautioned, however, that the study had limitations, including inconsistencies in the methodologies of the studies incorporated into the meta-analysis and systematic review. This includes variances in the baseline condition of opioid usage as well as disparities in the methods used to measure cannabis and opioid use. Furthermore, while the findings are relevant to cannabis usage in general, people with cannabis-use disorders could not benefit from them.

This research goes to show that patients who are using medical marijuana products from one of the many entities such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) need to consult an experienced professional before trying marijuana for the different health conditions they want help with.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Says Marijuana Won’t Enhance Performance But Will Make Exercising More Fun

A new study has found that smoking marijuana prior to a workout can make exercise more enjoyable and boost a person’s motivation. The study, which involved 42 volunteer runners, released its findings almost a decade after Colorado became the first state in the United States to offer legal sales of recreational cannabis.

The investigators took survey data and fitness measurements then assigned each volunteer a dispensary where they could pick a flower strain that contained mostly THC or CBD. Cannabidiol (CBD) and tetrahydrocannabinol (THC) are two of the primary compounds found in marijuana. Unlike TH, CBD doesn’t induce any high.

The volunteers had to go for follow-up visits where they ran on a treadmill for half an hour at a moderate pace. They also answered questions to evaluate how much they were enjoying themselves, how motivated they felt, how fast time seemed to pass, how hard the workout felt and if they felt any pain. The runners wore safety belts while running on the treadmill during the study period.

Across the board, study participants reported more intense euphoria and greater enjoyment. The researchers observed that this heightened mood was greater in the CBD group as compared to the THC group, which suggests that athletes may derive some benefits to mood while using a CBD-dominant strain.

Laurel Gibson, the study’s first author, highlighted that the bottom-line discovery was that marijuana before exercise seemed to increase enjoyment and positive mood during exercise, regardless of whether one used CBD or THC. She further noted that THC products, specifically, could make one use more effort during exercise. Gibson is a research fellow with the Center for Health and Addiction: Neuroscience, Genes and Environment.

The study’s findings as well as prior research by the researchers go against stereotypes that link marijuana with idleness/laziness.

Professor Angela Bryan, the study’s senior author, stated that new tools were needed to try get more individuals to move their bodies in enjoyable ways. Bryan, who specialized in psychology and neuroscience, noted that if marijuana was one of these tools, then it needed to be explored, with both its benefits and harms being considered.

A prior survey on marijuana users conducted by Bryan’s research group determined that 80% of respondents had used the drug before or after exercise. Despite this, minimal studies have been done looking into the link between marijuana and exercise.

The study’s findings were published in the “Sports Medicine” journal in December 2023.

Some prohibitionists have always asserted that marijuana is a performance-enhancing drug, but the cannabis industry and companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) may not be surprised that research has shown that the substance only improves one’s mood and not the workout itself.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Canadian Research Shows High Schoolers Admit Accessing Cannabis Is Harder Post-Legalization

A Canadian study involving high schoolers has found that cannabis legalization made it harder for minors to access the controversial plant. According to the newly published study, the portion of students who said they had easy access to marijuana has fallen recently.

This period of reduced minor access to cannabis also coincides with the Canadian government legalizing marijuana consumption for eligible adults and authorizing cannabis retail outlets across Canada. The study contradicts cannabis legalization opponents who claimed that removing criminal penalties for possessing and consuming cannabis would make it significantly easier for youth and young children to access cannabis.

Researchers used data from a multitopic student survey called the COMPASS Study to determine whether or not students have had increased access to cannabis post-legalization. The survey polled students from grades 9 to 12 in secondary schools in Alberta, Quebec, British Columbia and Ontario. The research team considered cannabis-related questions posted to the students during three separate time periods: 2018–19, 2019–20 and 2020–21.

The research team looked at the responses to the following two questions: “In the last 12 months, how often did you use marijuana or cannabis?” and “Do you think it would be difficult or easy for you to get marijuana if you wanted some?”

Team members discovered that the frequency among students who reported having easy access to cannabis dropped by 26.7% from 51.0% to 37.4% while rates of past-month cannabis use fell from 12.7% in the 2018–19 period to 7.5% in 2020–21, despite the country legalizing cannabis and launching legal sales.

Study participants were more likely to report gaining easier access to marijuana as they grew older, especially the participants who used cannabis as minors. Furthermore, the research team noted that students with a history of marijuana use had a higher likelihood of reporting having easy access to the drug post-legalization.

The initial coronavirus pandemic period “slightly impeded” ease of access to cannabis, but the issue went away as the pandemic continued.

Researchers say that while self-reported access to marijuana among minors has decreased since Canada legalized the drug and during the pandemic period, the chances of underage students reporting increased ease of access to cannabis rise as they grow older and advance through high school, especially among the third wave of participants in the most recent COMPASS survey data. Consequently, the researchers say, there is still a lot of room for improving cannabis control efforts and maximizing their impact to limit minor access to marijuana.

This research provides yet more evidence that legalizing marijuana and licensing companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) goes a long way in preventing minors from accessing the substance.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Interest in Growing Cannabis Grows in Ohio After Legalization Law Takes Effect

Ohio became the 24th state to legalize recreational cannabis in America after a voter-approved recreational marijuana initiative took effect. But, even though adults aged 21 years and older are now allowed to possess up to 2.5 ounces of cannabis flower and 1.5 grams of marijuana extract, the state has no authorized cannabis retailers.

Additionally, the state Division of Cannabis Control won’t start to process cannabis retailer applications until June 2024, meaning Ohio residents won’t have an avenue for legal adult-use purchases until late summer or even early fall.

The silver lining is that the cannabis legalization measure allows eligible Ohioans to cultivate up to six cannabis plants per household. Although the measure allowed up to 12 plants for a home with more than one eligible adult, a state senate bill reduced this limit to just six plants for every household. Ohio Governor Mike DeWine argued that the six plants per household allowed by Issue 2 were already more than a single person could consume alone.

For most Ohioans who want to consume cannabis in the meantime, home growing is the only legal means of doing so. Cannabis plants are fast growing and take three to four months to mature and bud. According to Cali Vybe Hydroponics from Finneytown, many more people have expressed interest in its products since Issue 2 passed and legalized recreational cannabis in Ohio.

For many, home cultivation provides a way to avoid pricey cannabis products from licensed shops and reduces the risk of consuming contaminated marijuana. Ohio Department of Commerce director Sherry Maxfield estimates that a mature homegrown cannabis plant can produce between 75 and 100 joints, meaning a sophisticated grower can yield significant cannabis in just a single year.

The fact that Ohio doesn’t have any authorized cannabis sellers despite legalizing recreational cannabis worries Senate President Matt Huffman because it could open the door for illicit sellers to carve out a market for themselves. Most states with cannabis markets, including California, which has the largest legal cannabis market on the globe, are struggling to compete with the cannabis black market.

Without a place to buy legal cannabis, many Ohioans may opt for the black market, especially since Issue 2 allows landlords to prohibit home-cannabis cultivation on their properties if it is specified on the lease. Cannabis from licensed sellers is several times more expensive than black-market marijuana due to numerous fees and taxes, resulting in reduced legal sales and a bountiful cannabis black market.

As this new market takes shape, it could easily attract established companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) that may be considering expanding into additional markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — AG Releases Ballot Explanation for Measure to Legalize Cannabis in South Dakota at the Polls

Last week, South Dakota’s attorney general released a ballot explanation for a prospective initiative that would legalize adult-use cannabis in the state and allow dispensaries to serve individuals aged 21 years of age and older. The resolution, which was sponsored by Emmett Reistroffer, would permit anyone aged 21 and older to cultivate, possess, ingest and distribute cannabis or cannabis paraphernalia. Reistroffer is the operations director at Genesis Farms, a medical marijuana company.

Under the measure, adults could also grow no more than 6 marijuana plants, with not more than 12 plants in every household; the can also possess up to three ounces of cannabis. It is important to note that driving while under the influence of cannabis would still be illegal, as would marijuana-related activity by those below the age of 21.

According to the final explanation by Attorney General Marty Jackley, property owners and employers could still prohibit the use of cannabis under the measure. Additionally, sales would occur via existing medical cannabis dispensaries, which could acquire dual-use licenses via the Department of Health.

With regard to possession, adults could possess no more than 24g of concentrated marijuana as well as other nonconcentrated marijuana products that contained less than 2,400mg of THC.

For the resolution to qualify for the 2024 ballot, organizers will need to collect no less than 17,510 signatures from registered voters by May 2024. Once placed on the ballot, a majority vote would allow the measure to pass.

In his latest statement, Reistroffer noted that he had no plans to campaign or collect signatures for the resolution in 2024 because he didn’t want to compete with the other legalization initiative that was already collecting signatures with the aim of being included in next year’s ballot.

Meanwhile, organizers for the other legalization proposal received the AG’s final summary a couple of months ago. The proposal, which is sponsored by South Dakotans for Better Marijuana Laws, would allow those aged 21 years of age and older to distribute marijuana. The initial form of this measure was amended to eliminate the word “sell.” This move made its language unclear, with the AG’s summary noting that legislative or judicial clarification was necessary.

A previous statement by Reistroffer highlighted some of the differences between his proposal and the South Dakotans for Better Marijuana Laws legalization measure. For instance, while his resolution included regulation and licensing via the health department, the other proposal did not touch on this matter. Additionally, while Reistroffer’s proposal would establish a path to legal sales that would generate sales tax for the state, the other proposal would generate no taxes. Furthermore, while his proposal focused primarily on legal sales and regulations, the other resolution mainly centered on noncommercial legalization.

Many marijuana companies, such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), may take an interest in the way the push to legalize cannabis in South Dakota plays out as the rift between different campaign groups could harm the reform movement.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Policy Analyst Says Marijuana Legalization ‘Inevitable’

A policy analyst from TD Cowen says that cannabis legalization in the United States is “inevitable” and believes that it is just a question of weathering a bumpy legislative landscape for the next several years. Originally, many analysts thought federal cannabis legalization was finally on track after the Democrats secured the House, Senate and White House, especially as President Joe Biden had based part of his campaign on cannabis reform.

However, while the Biden administration has taken some cannabis-related action, including issuing a mass pardon for people with certain cannabis-related convictions, the administration has barely made any moves to legalize cannabis at the federal level.

With President Biden’s first term fast approaching its end, many pundits and investors are quickly losing hope for federal cannabis legalization, particularly in the next couple of years. Capital investment in the state-legal cannabis industry is extremely low, and the AdvisorShares Pure U.S. Cannabis ETF, current holder of all U.S.-based marijuana companies, is trading at just $6.80 a share down from around $52 a share in early 2021.

Federal prohibition has made operating in the cannabis sector almost untenable; cannabis businesses are barred from interstate commerce, they struggle to obtain investment and financing, and they aren’t allowed to make normal business tax deductions. Even so, TD Cowen policy analyst Jaret Seiberg says federal legalization is inevitable. Polls show that a majority of the American population is in favor of either decriminalization or outright legalization, and a cadre of top lawmakers has thrown their weight behind cannabis reform.

Bipartisan legislation such as the SAFER Banking Act seeks to legitimize the cannabis sector by allowing industry players to access financial services from banking institutions. Senate Majority Leader Chuck Schumer and other senators have also been working on a bill that would legalize cannabis at the federal level.

In addition, a group of Massachusetts cannabis businesses has filed a lawsuit alleging that the Controlled Substances Act, which classifies cannabis as a Schedule I controlled drug, is an unconstitutional infringement on the power of states with legal cannabis. Although a favorable ruling wouldn’t make interstate cannabis trade any easier, it would significantly ease the operations of already existing cannabis businesses by granting them access to essential financial services, such as bank accounts and cashless payments.

Legalization may also be spurred by executive action. For instance, Biden recently asked the U.S. Department of Health and Human Services (HHS) to review marijuana’s federal status as a controlled substance. Subsequently, a letter dated Aug 29, 2023, which was obtained by Bloomberg, revealed that a top HHS official had recommended that the Drug Enforcement Agency (DEA) reschedule cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III.

The cannabis industry, including enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), awaits any definitive action taken by the DEA as this will have a major effect on the trajectory of the marijuana industry in the United States.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Genomic Study Gives Insights into Why Individuals Suffer from CUD

An examination of the genetic makeup of more than a million individuals, spearheaded by researchers at Yale, has provided valuable insights into the biological foundations of marijuana use disorder and how it relates to mental health issues, substance misuse (including tobacco) and potentially even a higher risk of lung cancer.

The study examined the genomes of participants from a range of ancestry groups, utilizing information from many genomic databases in addition to the extensive genetic data bank of the United States Veterans Affairs’ Million Veteran Program (MVP).The analysis revealed many genetic variations connected to marijuana use disorder, providing insight into a range of behavioral and physical problems related to the condition.

The study, published in the “Nature Genetics Journal” this month, was led by Daniel Levy, an assistant professor of psychiatry, and Joel Gelernter, a professor at the Foundations Fund of Psychiatry and Genetics and Neuroscience.

According to the Centers for Disease Control and Prevention (CDC), 48 million individuals, or 18% of the American population, used cannabis at least once in 2019, making cannabis the most widely used federally illegal substance in the country. Previous research indicates that roughly 10% of cannabis users develop an addiction, while three out of ten users have a marijuana use disorder, which is defined as an unfavorable pattern of use that results in clinical impairment or suffering. Furthermore, another study found that those who began using marijuana throughout childhood or adolescence and who use it more regularly have a higher chance of developing the disorder.

The newly unveiled genetic findings provide nuanced views into the underpinnings of this phenomenon and its potential ramifications on health. Notably, certain genetic variants associated with marijuana use disorder were identified in genes responsible for encoding three distinct types of neuron receptors, indicating an elevated risk of developing this disorder.

Intriguingly, there was a correlation found between these same genetic variations and an elevated risk of lung cancer. The researchers, however, underscore the necessity for further investigation to disentangle the influences of tobacco smoking and other factors on cancer diagnosis from those associated with cannabis use.

Joel Gelernter emphasized the significance of this study, labeling it the most extensive genome-wide exploration of marijuana use disorder to date. He also noted that as cannabis legalization and decriminalization efforts gain momentum across states, studies of this nature are instrumental in comprehending the accompanying health risks.

This study helps to clarify that individuals who develop cannabis use disorder often have a genetic predisposition to this condition. For that reason, most members of the general population can safely use marijuana products from any of the many companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) for recreational or medical reasons without having a high risk of developing CUD.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Survey Shows Growing Investor Interest in Cannabis MSOs

A recent survey indicates a growing optimism among institutional investors towards U.S. marijuana multistate operators (MSOs). Conducted by Calgary-based ATB Capital Markets, the survey involved 23 institutional investors, primarily hedge funds.

Frederico Gomes, the lead author of the report and a marijuana equity analyst, highlighted the increased bullish sentiment among investors, driven primarily by the potential rescheduling of marijuana by the federal government. The survey reveals that about 61% of respondents believe U.S. marijuana MSOs will outperform the S&P 500 in the next year. However, despite this positive sentiment, Gomes notes that the capital influx has not yet aligned with the bullish outlook from an institutional perspective.

The likelihood of the U.S. government rescheduling cannabis from Schedule 1 to 3 within the next 18 months was perceived as 75% by the surveyed investors. Yet, the majority of them reported either no change or reduced exposure to MSOs in the past six months. This indicates a cautious approach, possibly due to past regulatory uncertainties.

Investors expressed a 50% probability of Congress passing the SAFER Banking Act, legislation facilitating financial institutions to serve state-legal marijuana businesses without federal repercussions. This uncertainty is attributed to past failures in marijuana banking reform legislation and political ambiguities surrounding the new GOP speaker of the U.S. House of Representatives, Mike Johnson.

ATB sought to understand the factors influencing investors’ willingness to invest more in MSOs. Cannabis rescheduling emerged as the top priority for nearly 61% of respondents. On the other hand, the possibility of more MSO stock listings on the Toronto Stock Exchange (TSE) was deemed to be the least significant element.

Regarding capital allocation preferences, investors indicated a preference for MSOs to prioritize deleveraging and debt repayment, with organic growth being the second-most desired behavior. Mergers and acquisitions were not favored, and share repurchases ranked as the least-desired way for MSOs to allocate capital.

While investors displayed increased bullishness towards U.S. MSOs, their outlook on Canadian licensed retailers and producers was less optimistic, with 60% expecting underperformance compared to the S&P 500. The negative sentiment in Canada is attributed to poor operating results and shareholder dilution.

Interestingly, the survey revealed that only 52% of investors expressed interest in Canadian marijuana retailers and producers. This disparity can point to a possible acquisition opportunity for investors who are not conventional thinkers in the Canadian marijuana market.

Gomes noted that investors are wary due to past setbacks and are waiting for signs of improvement in terms of profitability and sustainable operations. The report notes that achieving sustainable profitability and positive free cash flow is seen as the most crucial factor, followed by a reduction in excise taxes.

As the policy direction of the United States becomes more clear after the U.S. Drug Enforcement Administration releases its rulemaking recommendation, cannabis companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) may attract more investor interest.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Higher Increase in Home Valuations in Legal States vs. Cannabis Prohibitionist States

Home values in states with legal cannabis markets have grown at significantly faster rates over the past decade compared to prohibitionist states. According to a Leafly and Real Estate Witch study, homes in cannabis states are 41% higher in value than homes in states without legal cannabis markets.

The paper looked at the potential impact of recreational or medical cannabis markets on average American home prices from 2014–2023.

Although states such as California began legalizing medical cannabis more than a decade ago, the past decade has seen a multitude of states legalize the controversial plant. With dozens of states now allowing medical and recreational cannabis, tens of millions of Americans now have access to either medical or adult-use marijuana.

However, several states still outlaw both recreational and medical cannabis, meaning there are plenty of Americans who are still criminalized for cannabis possession and use.

Cannabis remains the most used drug in the country, even in states that still criminalize it, and it seems the drug may now be affecting real estate values across the country. The analysis revealed that average home prices in states with recreational cannabis markets increased by $185,075 since 2014 compared to $136,092 in states without adult-use markets.

As a result, average home prices in recreational cannabis states hit $417,625 by the end of the study period while average home prices in nonrecreational marijuana states were 41% lower at $295,338. States with medical marijuana markets also registered faster home value growth compared to states without medical cannabis reform, growing by an average of $166,609 since 2014 compared to $137,320 in prohibitionist states.

According to the report, it isn’t surprising that states that embraced cannabis reform are registering significant increases in home values because real estate always appreciates over time. However, the gap between states with cannabis markets and prohibitionist states “sticks out like a green thumb,” the report noted.

There was even evidence of cannabis reform affecting home values at local levels with cities that had licensed cannabis retailers seeing an average home price increase of $168,292 since 2014. In comparison, cities without cannabis dispensaries saw an increase of only $100,933 in the same period, indicating that cannabis legalization may have some effect on property values.

Leafly vice president of brand and communication Josh deBerge said the report is evidence of what many cannabis community insiders have known for a long time: cannabis reform does not diminish property values. Rather, licensing cannabis firms such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) boosts demand for residential and commercial property.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com